This Powerful Drug Combo Cuts Prostate Cancer Deaths by 40%

This powerful drug combo cuts prostate cancer deaths by 40%

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 patients worldwide and was led by Cedars-Sinai researchers. Experts call it a game changer that’s likely to reshape treatment guidelines for aggressive prostate cancer.

Prostate Cancer: Drug combo lowers death risk by 40% in aggressive cases

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new treatment.

Drug combo cuts risk of death in advanced prostate cancer by 40%, clinical trial finds

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.

Cancer drug combo slashes risk of death by more than 40%

Breakthrough findings reveal a drug combination reduces advanced prostate cancer death risk by 40.3%, offering new hope for survival.

Enzalutamide/Leuprolide Regimen Reduces Risk of Death in Prostate Cancer

At 8 years follow-up, patients with recurrent prostate cancer in the enzalutamide/leuprolide arm had an OS rate of 78.9% vs 69.5% vs leuprolide alone.